The present invention relates to a combined preparation comprising (i) amodulator of pyruvate kinase M2 (PKM2)activity, and (ii) an agent providing high mobility group box 1 (HMGB1)polypeptide or a derivative thereof. The present invention alsorelates to the aforesaid combined preparation for use as a medicament and foruse in the treatment of inappropriate cellular proliferation,preferably in the treatment of cancer. Moreover, the present invention relatesto a method for determining whether a subject sufferingfrom inappropriate cellular proliferation is amenable to a treatmentcomprising administration of a modulator of PKM2 activity as theonly PKM2 inhibitor and to treatment methods related thereto.
